Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Recent & Breaking News (NDAQ:SCYX)

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2022

SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

GlobeNewswire March 2, 2022

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022

GlobeNewswire February 10, 2022

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 3, 2022

SCYNEXIS to Participate in Upcoming January Investor Conferences

GlobeNewswire January 6, 2022

SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million

GlobeNewswire December 22, 2021

BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients

GlobeNewswire December 20, 2021

European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS' Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis

GlobeNewswire December 15, 2021

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

GlobeNewswire December 6, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2021

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

GlobeNewswire December 3, 2021

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What's New Award in the Health Category

GlobeNewswire December 1, 2021

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

GlobeNewswire November 29, 2021

SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection

GlobeNewswire November 23, 2021

SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2021

SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp

GlobeNewswire November 9, 2021

SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

GlobeNewswire November 3, 2021

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

GlobeNewswire October 21, 2021

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

GlobeNewswire October 13, 2021

SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis

GlobeNewswire October 11, 2021